Articles

Practical management of newly-diagnosed multiple myeloma: 2018 update for transplant eligible patients

BJH - volume 10, issue 3, may 2019

N. Meuleman MD, PhD, C. Doyen MD, K.L. Wu MD, PhD, P. Mineur MD, G. Bries MD, PhD, A. Kentos MD, PhD, L. Michaux MD, PhD, M. Delforge MD, PhD

With the introduction of immunomodulatory agents and proteasome inhibitors, major improvements have been achieved in the treatment and outcome of multiple myeloma. Different treatment combinations are now in use and newer therapies are being developed. Nevertheless, autologous stem cell transplantation remains the corner stone of therapy for fit, newly-diagnosed multiple myeloma patients. Based on an extensive review of the recent literature, we propose recommendations on myeloma care, to be used by haematologists as a reference for daily practice.

(BELG J HEMATOL 2019;10(3):113–21)

Read more

Practical management of newly-diagnosed multiple myeloma: 2018 update for transplant eligible patients

BJH - volume 9, issue Multiple Myeloma Special Edition, december 2018

N. Meuleman MD, PhD, C. Doyen MD, K.L. Wu MD, PhD, P. Mineur MD, G. Bries MD, PhD, A. Kentos MD, PhD, L. Michaux MD, PhD, M. Delforge MD, PhD

SUMMARY

With the introduction of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), major improvements have been achieved in the treatment and outcome of multiple myeloma (MM). Different treatment combinations are now in use and newer therapies are being developed. Nevertheless, autologous stem cell transplantation (ASCT) remains the corner stone of therapy for fit, newly-diagnosed MM patients. Based on an extensive review of the recent literature, we propose recommendations on myeloma care, to be used by haematologists as a reference for daily practice.

Read more

PP02 Monocentric retrospective study of 138 therapy-related myeloid neoplasms

BJH - 2018, issue Abstract Book BHS, february 2018

H. Claerhout MD, E. Lierman PhD, L. Michaux MD, PhD, G. Verhoef MD, PhD, N. Boeckx MD, PhD

Read more

PP06 Hereditary predisposition syndromes to malignant hemopathies (HPSMH)

BJH - 2018, issue Abstract Book BHS, february 2018

S. Dupriez , A. Ferrant , M.C. Vekemans MD, B. Brichard MD, PhD, L. Michaux MD, PhD, T. Connerotte MD, E. Van den Neste MD, PhD, C. Vermylen , L. Knoops MD, PhD, C. Graux MD, PhD, F. Duhoux MD, PhD, C. Lambert MD, PhD, X. Poiré MD, PhD, H.A. Poirel MD, PhD

Read more

P17 Concurrent driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients

BJH - 2018, issue Abstract Book BHS, february 2018

L. De Roeck , L. Michaux MD, PhD, K. Debackere MD, E. Lierman PhD, P. Vandenberghe MD, PhD, T. Devos MD, PhD

Read more

PP31 Roles of microRNAs in myeloid malignancies driven by activated tyrosine kinases

BJH - volume 8, issue Abstract Book BHS, february 2017

M. Claus , A. Essaghir , P. Saussoy MD, PhD, L. Michaux MD, PhD, J.B. Demoulin , V. Havelange MD, PhD

Read more

P11 Low-pass sequencing of plasma cell DNA and of circulating cell-free DNA for the detection of copy number aberrations and early response monitoring in multiple myeloma

BJH - volume 8, issue Abstract Book BHS, february 2017

B. Dewaele PhD, S. Smits , L. Dehaspe , N. Brison , J. Ding , J. Van Houdt , H. Lemmens , L. Michaux MD, PhD, J. Vermeesch , P. Vandenberghe MD, PhD

Read more